Building on our success in endocrinology rare diseases, we aim to advance cancer treatments and improve patient outcomes

Over the last few decades, groundbreaking oncology research has accelerated our understanding of cancer biology and the mechanisms involved in these devastating diseases. This knowledge has led to the development of new treatments – from immunotherapy to targeted therapies – that have transformed cancer care.

With TransCon™, we aim to go one step further by creating therapies with better efficacy without increasing toxicity. The result could be solving the limitations of current treatments to ultimately help improve patient outcomes.

Our TransCon technologies may advance treatment of cancer.

An innovative approach

We believe TransCon is well-suited for oncology applications given the large number of validated targets with known limitations. By applying our unique algorithm for product innovation to clinically validated targets, we believe we can increase the likelihood of success, accelerate timelines to the clinic, and improve outcomes currently limited by suboptimal efficacy and systemic toxicity.

Our TransCon product candidates offer the potential to treat more patients with new combination and multi-agent regimens that otherwise would not be feasible.

TransCon technologies enable the sustained release of a parent drug – from approximately one day to over six months – depending on the treatment goal. This means therapeutic levels can be maintained without the need for frequent administration, avoiding high peaks in circulating drug levels. With this approach, we are working to prolong the exposure of drugs at efficacious levels, without reaching the high levels of toxicity that often complicate oncology therapeutic regimens.

TransCon Technologies in Oncology

Localized (intratumoral) release

Applies TransCon technology to release a therapeutic inside the tumor to minimize systemic toxicity and maximize tumor exposure
Uses a unique hydrogel carrier to provide sustained levels of drug locally at the tumor site
Designed to facilitate anti-tumor effects via intratumoral concentrations and activation of systemic immune response
Hydrogel carrier system recognized as an innovative technology and part of the U.S. FDA Emerging Technology Program

Systemic release

Foundation of our endocrinology rare disease pipeline
Enables design of potential product candidates that provide prolonged drug exposure at efficacious levels without reaching toxic levels
Soluble carrier inactivates and shields the drug from clearance, allowing sustained systemic release of the drug under physiologic conditions

Oncology pipeline

We have one oncology candidate in clinical development, TransCon IL-2β/y.

TransCon IL-2 β/γ

Technology: Systemic

Designed for prolonged exposure of an interleukin-2 (IL-2) variant that selectively activates the IL-2 receptor beta/gamma (IL-2Rβ/γ) with minimal binding to the IL-2 receptor alpha (IL-2Rα)
Potential to provide potent anti-tumor effects with reduced risk of toxicity